PE66898A1 - Inhibicion de las metaloproteasas de matriz por acidos biariloxobutiricos sustituidos - Google Patents

Inhibicion de las metaloproteasas de matriz por acidos biariloxobutiricos sustituidos

Info

Publication number
PE66898A1
PE66898A1 PE1997000365A PE00036597A PE66898A1 PE 66898 A1 PE66898 A1 PE 66898A1 PE 1997000365 A PE1997000365 A PE 1997000365A PE 00036597 A PE00036597 A PE 00036597A PE 66898 A1 PE66898 A1 PE 66898A1
Authority
PE
Peru
Prior art keywords
methyl
oxo
biariloxobutiric
inhibition
acids
Prior art date
Application number
PE1997000365A
Other languages
English (en)
Inventor
Brian R Dixon
David R Brittelli
Zandt Michael C Van
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of PE66898A1 publication Critical patent/PE66898A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/04—1,2,3-Triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE r ES 0 o 2; "T" ES PREFERENTEMENTE Cl; R40 ES -CH2OCH2OCH2Ph, (4-OXO-1,2,3-BENZOTRIACIN 3(4H)-IL)METIL, ((1-PIRROLIDINILTIOXOMETIL)TIO)METIL, (1,1-DIOXIDO-3-OXO-1,2-BENCISOTIAZOL-2(3H)-IL)METIL O (1-OXO-2(1H)-FTALAZINIL)METIL, ENTRE OTROS. ESTOS COMPUESTOS ACTUAN COMO INHIBIDORES DE LAS METALOPROTEASAS DE LA MATRIZ (MMP) QUE POSEEN MEJOR BIODISPONIBILIDAD Y ESTABILIDAD BIOLOGICA, SIENDO UTILES PARA: (a) MITIGAR LOS EFECTOS DE LA OSTEOARTRITIS O ARTRITIS REUMATOIDEA, ENTRE OTROS; (b) RETARDAR LAS METASTASIS DE TUMORES O LA PERDIDA DEGENERATIVA DEL CARTILAGO POSTERIOR A UNA LESION ARTICULAR TRAUMATICA; (c) REDUCIR LA TROMBOSIS CORONARIA; O (d) PRACTICAR EL CONTROL DE LA NATALIDAD
PE1997000365A 1996-05-15 1997-05-12 Inhibicion de las metaloproteasas de matriz por acidos biariloxobutiricos sustituidos PE66898A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64849396A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
PE66898A1 true PE66898A1 (es) 1998-10-22

Family

ID=24601014

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000365A PE66898A1 (es) 1996-05-15 1997-05-12 Inhibicion de las metaloproteasas de matriz por acidos biariloxobutiricos sustituidos

Country Status (25)

Country Link
EP (1) EP0923530B1 (es)
JP (1) JP3354942B2 (es)
CN (1) CN1100748C (es)
AR (1) AR007098A1 (es)
AT (1) ATE275123T1 (es)
AU (1) AU714207B2 (es)
BR (1) BR9709086A (es)
CA (1) CA2254731C (es)
CO (1) CO5011061A1 (es)
DE (1) DE69730508T2 (es)
DK (1) DK0923530T3 (es)
ES (1) ES2227696T3 (es)
HK (1) HK1021897A1 (es)
HR (1) HRP970244B1 (es)
ID (1) ID17291A (es)
MY (1) MY132463A (es)
PA (1) PA8429701A1 (es)
PE (1) PE66898A1 (es)
PT (1) PT923530E (es)
SV (1) SV1997000036A (es)
TN (1) TNSN97083A1 (es)
TW (1) TW539672B (es)
WO (1) WO1997043239A1 (es)
YU (1) YU18597A (es)
ZA (1) ZA974030B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925637A (en) * 1997-05-15 1999-07-20 Bayer Corporation Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
EP1031349A1 (en) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
GB9922710D0 (en) * 1999-09-24 1999-11-24 Bayer Ag Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
JP2004359546A (ja) * 2001-03-15 2004-12-24 Ono Pharmaceut Co Ltd ヒドロキサム酸誘導体、それらの非毒性塩およびそれらのプロドラッグ体を有効成分として含有する、固形癌の予防および／または治療剤
JPWO2002074298A1 (ja) * 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
KR101405823B1 (ko) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US20120040974A1 (en) * 2008-08-18 2012-02-16 Yale University Mif modulators
US20170022171A1 (en) 2014-04-03 2017-01-26 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentanecarboxylic acids and their use
CN106661008A (zh) * 2014-04-03 2017-05-10 拜耳制药股份公司 用于治疗呼吸道疾病的2,5‑二取代的环戊烷甲酸
WO2015150362A2 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Chirale 2,5-disubstituierte cyclopentancarbonsäure-derivate und ihre verwendung
CN113979992B (zh) * 2021-11-19 2022-06-24 西安欧得光电材料有限公司 一种3-取代二苯并噻吩及其合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69512891T2 (de) * 1994-01-22 2000-02-24 British Biotech Pharmaceuticals Ltd., Cowley Metalloproteinaseinhibitoren

Also Published As

Publication number Publication date
JPH11510821A (ja) 1999-09-21
ID17291A (id) 1997-12-18
TNSN97083A1 (fr) 2005-03-15
ZA974030B (en) 1998-02-19
CN1100748C (zh) 2003-02-05
YU18597A (sh) 2001-12-26
MY132463A (en) 2007-10-31
SV1997000036A (es) 1998-07-20
JP3354942B2 (ja) 2002-12-09
BR9709086A (pt) 1999-08-03
PT923530E (pt) 2004-12-31
ATE275123T1 (de) 2004-09-15
EP0923530A1 (en) 1999-06-23
AU714207B2 (en) 1999-12-23
HRP970244B1 (en) 2005-06-30
DE69730508D1 (de) 2004-10-07
HK1021897A1 (en) 2000-07-14
EP0923530B1 (en) 2004-09-01
HRP970244A2 (en) 1998-04-30
AR007098A1 (es) 1999-10-13
CN1225621A (zh) 1999-08-11
CA2254731C (en) 2004-07-20
CA2254731A1 (en) 1997-11-20
DE69730508T2 (de) 2005-09-29
DK0923530T3 (da) 2005-01-03
TW539672B (en) 2003-07-01
AU3122097A (en) 1997-12-05
PA8429701A1 (es) 2000-05-24
CO5011061A1 (es) 2001-02-28
WO1997043239A1 (en) 1997-11-20
ES2227696T3 (es) 2005-04-01

Similar Documents

Publication Publication Date Title
PE66898A1 (es) Inhibicion de las metaloproteasas de matriz por acidos biariloxobutiricos sustituidos
UY27167A1 (es) Inhibidores de piridina de metaloproteinasas de la matriz
DK0726892T3 (da) (E)-20(22)-dehydrovitamin D-forbindelser
NO942765L (no) Anvendelse av substituerte adenin derivater for behandling av multiple sclerose
AR014261A1 (es) Compuestos hipolipidemicos de benzotiazepina, composiciones y proceso para su preparacion
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
ES2067314T3 (es) 3-benzacepin-zonas sustituidas por un grupo benzociclobutilo o indanil-alquil-amino-alquilo, utiles en el tratamiento de las afecciones cardiovasculares.
BR9804437A (pt) Compostos para a osteoporose
DK0679157T3 (da) Nye 3,4-diarylthiophener og analoge deraf til anvendelse som antiinflammatoriske midler
PT1297851E (pt) Inibicao de histona-desacetilase como tratamento para hipertrofia cardiaca
MX9203313A (es) Derivados de quinolina y sus usos para controlar el crecimiento indeseado de plantas.
UY24409A1 (es) Inhibidores de la matriz metaloproteasa
PE20020305A1 (es) 2-(4-PIRIDIL) AMINO-6-DIALCOXIFENIL-PIRIDO [2,3-d] PIRIMIDIN-7-ONAS COMO INHIBIDORES DE LA TIROSINA QUINASA
DE69617701D1 (de) 3-pyridyloxyalkyl heterozyklische ether-verbindungen, verwendbar zur steuerung von chemischer synaptischer transmission
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
AR020787A1 (es) Derivados de acidos diaminopropionicos
BR9903984A (pt) Composição aquosa que contém peptìdio farmaceuticamente efetivo, utilização dessa composição, processo para a produção de uma composição farmacêutica para aplicação local e processo para aumentar a atividade de um polipeptìdio
MX9300031A (es) Derivados de piperazina, procedimiento para su preparacion y composicion farmaucetica que los contiene.
DE69911980D1 (de) Pyrimidinonderivate zur behandlung von atheroscleros
ES2038609T3 (es) 4,5-dihidroisoxazol, 3,5 disustituido como inhibidores de transglutaminasa.
FI935360A (fi) Guanidiinialkyyli-1,1-bifosfonihappojohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö
CO4700469A1 (es) 3-[4-(4(4-cianofenil)-1-piperazinanil)butil]-5]ciannoindol y su proceso de obtencion .
ES2150808T3 (es) Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.
BG105736A (en) 2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
ES2059301T3 (es) Utilizacion de inhibidores de la enzima convertidora de angiotensina para el tratamiento de la aterosclerosis, trombosis y de la enfermedad vascular periferica.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed